

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/41187811>

Improved Synthesis of the Two-Photon Caging Group 3-Nitro-2-Ethyldibenzofuran and Its Application to a Caged Thymidine Phosphoramidite

ARTICLE *in* ORGANIC LETTERS · MARCH 2010

Impact Factor: 6.36 · DOI: 10.1021/ol902807q · Source: PubMed

CITATIONS

19

READS

47

3 AUTHORS, INCLUDING:



Rajendra Uprety

Memorial Sloan-Kettering Cancer Center

12 PUBLICATIONS 196 CITATIONS

SEE PROFILE



Alexander Deiters

University of Pittsburgh

135 PUBLICATIONS 5,049 CITATIONS

SEE PROFILE

Published in final edited form as:


Org Lett. 2010 March 5; 12(5): 916–919. doi:10.1021/ol902807q.

Improved synthesis of the two-photon caging group 3-nitro-2-ethylidibenzofuran and its application to a caged thymidine phosphoramidite

Hrvoje Lusic, Rajendra Uprety, and Alexander Deiters*

Department of Chemistry, North Carolina State University, Raleigh, NC 27695

Abstract



A new and efficient route to the recently reported 3-nitro-2-ethylidibenzofuran caging group was developed. Furthermore, its installation on a thymidine phosphoramidite is described. This caging group is efficiently removed through light-irradiation at 365 nm.

Photo-labile protecting groups (caging groups) are important tools in the investigation of biological processes. Cleavage of caging groups by light (decaging) is a mild and non-invasive technique that is completely orthogonal to other chemical processes in a biological system. Moreover, caged molecules offer a unique way to study biological systems, because they allow for precise temporal and spatial control over the chemical and biological (re)activity of molecules. This approach has been successfully applied to the photochemical regulation of the activity of small molecules, peptides, proteins, and oligonucleotides.^{1–4} Several caging strategies for oligomers have been developed: statistical caging of the DNA or RNA backbone,^{5–7} incorporation of photo-cleavable linkers into the oligomer strand,^{8–11} and lastly incorporation of caged nucleotide building blocks into oligonucleotides.^{12–18}

All base-caged phosphoramidites developed to date require UVA irradiation of approximately 360 nm for efficient decaging. Disadvantages of UVA light include limited tissue penetration, potential photodamage, and difficulties to achieve high-precision three-dimensional focusing of the photoexcitation process. A solution to these problems is the application of two-photon excitation techniques. Under two-photon excitation conditions, a molecule that has an absorbance maximum at 350 nm can be excited by simultaneously absorbing two photons of precisely half the energy, i.e. 700 nm.^{19, 20} Light at near-IR, or IR wavelengths (between 700–1000 nm) exhibits deeper tissue-penetration (e.g. up to 8 mm in bovine muscle tissue),^{21–23}

alex_deiters@ncsu.edu.

Supporting Information Available. Synthetic protocols and analytical data, stability tests and decaging experimentals, copies of ¹H and ¹³C NMR spectra of new compounds.

causes less photodamage, and can be focused much more precisely (down to a 1 fL volume).^{20, 24}

The main characteristic of a good two-photon caging group is a high-two photon decaging cross-section δ_u , which is defined as a product of a two-photon absorbance cross-section δ_a and a two-photon decaging quantum yield Q_u .²⁵ Ideally δ_u should exceed 0.1 Goeppert-Mayer (GM) for biological experiments in order to avoid potential tissue damage caused by high laser powers.^{25–27} The two most commonly employed two-photon caging groups are 6-bromo-7-hydroxycoumarin-4-methyl (Bhc), with a δ_u of 0.72 GM at 740 nm;²⁵ and 8-bromo-7-hydroxyquinoline (BHQ), with a δ_u of 0.59 GM at 740 nm.²⁸ Both have been employed to cage a variety of substrates, including carboxylic acids, phosphates, carbonates, carbamates, diols, aldehydes, and ketones.^{24, 25, 27–31} Bhc and BHQ caging groups decay according to a solvent-assisted heterolysis mechanism.^{24, 26} This makes them unsuitable for direct caging of substrates with high pKa values,^{32, 33} such as alcohols, phenols, amines, and amides, hampering their application in the caging of nucleotide bases. Recently, Furuta and coworkers have prepared a pair of Bhc-caged nucleosides through the installation of the Bhc group via a carbamate linkage at the 6-NH₂ of deoxyadenosine and the 4-NH₂ of deoxycytidine.³¹ However, the caging group carbamate linkage in these phosphoramidites would hydrolyze during the final step (base deprotection with NH₄OH, or MeNH₂) of the automated oligonucleotide synthesis (as observed by us for similar structures; data not shown), and neither compound has been converted into a phosphoramidite. Additionally, the overall yields for the synthesis of Bhc-caged nucleosides were low due to difficulties associated with the carbamate formation.

In order to develop a suitable and easily accessible two-photon caged phosphoramidite for DNA synthesis, we decided to combine our 6-nitropiperonyloxymethyl (NPOM) caging group strategy^{17, 18, 34, 35} with the recently discovered 3-nitro-2-ethyl-dibenzofuran (NDBF) group (**1**) (Figure 1), which decages via a classical Norrish type II mechanism, enabling efficient caging and decaging of less acidic functional groups,³³ while displaying an excellent δ_u of 0.6 GM (at 710 nm).

Despite its excellent photochemical properties and potential to cage diverse substrates, no application of the NDBF group has been reported since its discovery. We believe that this is due to difficulties accessing it synthetically. Reported syntheses of the alcohol **1** and the bromides **2–3** (Figure 1) are rather low yielding and often involve laborious and difficult purification steps.^{33, 36} In addition to developing our own synthetic path to **1–2**, we have also synthesized the chloromethylether **4** (Figure 1), which was modeled after the NPOM caging group for caging of nitrogen heterocycles such as nucleotide bases.^{17, 18, 34}

The previously published synthesis, starting from dibenzofuran, produced (3-nitrodibenzofuran-2-yl)-ethanol (**1**) in 4% total yield over 6 steps, and 1-bromo-1-(3-nitrodibenzofuran-2-yl)-ethane (**2**) in 10% overall yield over 4 steps.^{33, 36} An alternative synthetic strategy leading to the caging group 1-bromo-1-(3-nitrodibenzofuran-2-yl)-methane (**3**), starting from 1-chloro-2-nitrobenzene and *p*-cresol, afforded the final product **3** in only 1% total yield over 6 steps.³⁶

We developed an optimized synthetic route to the NDBF group **4** (Scheme 1), enabling us to synthesize sufficient quantities of the caged phosphoramidite **11**, to be used in automated DNA synthesis. Our approach starts from commercially available 4-fluoro-2-nitrobenzaldehyde (**5**) and 2-iodophenol by employing an Ullmann coupling, using CuBr and K₂CO₃ in pyridine, at 60 °C, to form the diaryl ether **6** in 77% yield. The aldehyde **6** was subsequently alkylated using AlMe₃ in DCM, affording the secondary alcohol **7** in 95% yield. The bottle-neck of the synthesis was the formation of the dibenzofuran ring, which we accomplished via a Heck

reaction by heating **7** in the presence of catalytic amounts of Pd(OAc)₂, using Cs₂CO₃ as a base in DMAc at 80 °C. The caging group **1** was isolated as the sole regioisomer in 38% yield (28% total yield over three steps). Unfortunately, attempts to improve the yield of the ring-closure reaction failed. Substituting Cs₂CO₃ for alternative bases (K₂CO₃, DIPEA, DBU), and changing the solvent (DMSO, toluene, THF) all provided lower yields. Increasing the temperature or employing microwave irradiation also resulted in lower yields, and the formation of multiple side-products hampering purification. Also, cyclization attempts with the aldehyde **6** led to diminished yields. Subsequently, the alcohol **1** was converted to a bromide using PBr₃ in DCM, at 0 °C, in 70% yield, thus affording the caging group **2** in 19% over 4 steps. Alternatively, the caging group **1** was protected as a methylthiomethyl ether **8** in 70% yield, using Me₂S and benzoyl peroxide in CH₃CN, at 0 °C. The MTM-derivative **8** was then converted to the caging group **4**, employing SO₂Cl₂ in DCM, at 0 °C. The caging group **4**, was directly used in the caging of thymidine without purification.

The synthetic path to **1**, **2**, and **4** presented herein, is substantially shorter and offers markedly improved yields. Our synthesis also avoids the need for laborious purifications required for the separation of different regioisomers and multiple reaction side-products.

To prepare an NDBF-caged thymidine phosphoramidite for DNA synthesis, we reacted 5'-*O*-(4,4'-dimethoxytrityl)thymidine (**9**, synthesized in one step from thymidine following a literature procedure³⁷) with the caging group **4** (Scheme 2), using Cs₂CO₃ in DMF, at 0 °C to r.t., obtaining **10** in 73 yield. Gratifyingly, the free 3'-OH group was unreactive under those conditions, thus obviating additional protecting group chemistry. The NDBF-caged thymidine **10** was then converted to the phosphoramidite **11** in 80% yield using 2-cyanoethyl-*N,N*-diisopropylchlorophosphoramidite, employing DIPEA as a base in DCM, at r.t.

The stability of the NDBF-caged thymidine towards DNA synthesis was then studied. The installed caging group was found to be completely stable under several different conditions commonly used for the removal of protecting groups from the 5'-OH and the nucleotide bases, as well as oligonucleotide cleavage from the support resin: a) conc. NH₄OH, 65 °C, 16 h; b) 33% MeNH₂ in EtOH, 55 °C, 16 h; c) 5% TFA in DCM, rt, 1 h (see Supporting Information).¹⁷ Decaging of the NDBF-thymidine was tested in CH₃OH (0.1 mM) by conducting a time course of UV irradiation over 5 minutes (hand-held Spectroline ENF-280C UV lamp, at 365 nm, 23 W) followed by HPLC analysis. It was found that NDBF-thymidine decages rapidly with a half-life of about 30 seconds (see Figure 2 and Supporting Information).

In summary, we have developed an improved synthetic route to the recently discovered two-photon caging group 3-nitro-2-ethylbenzofuran (NDBF). Due to its favorable photochemical fragmentation mechanism, we were able to apply the NDBF group in the successful caging of a thymidine phosphoramidite. This caging moiety is stable to standard DNA synthesis conditions and thus can be readily incorporated into the synthesis of photo-controllable oligonucleotides for biological applications.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.


Acknowledgments

Financial support from the National Institutes of Health (R01GM079114) is acknowledged. A.D. is the recipient of a Beckman Young Investigator Award, a Cottrell Scholar Award, an NSF CAREER Award, and a TEVA USA Scholars Grant.

References

1. Goeldner, M.; Givens, RA., editors. *Dynamic Studies in Biology: Phototriggers, Photoswitches and Caged Biomolecules*. Wiley-VCH; Weinheim: 2005.
2. Young DD, Deiters A. *Org Biomol Chem* 2007;5:999–1005. [PubMed: 17377650]
3. Mayer G, Heckel A. *Angew Chem Int Edit* 2006;45:4900–4921.
4. Lee H, Larson DR, Lawrence DS. *ACS Chem Biol* 2009;4:409–427. [PubMed: 19298086]
5. Ando H, Furuta T, Tsien RY, Okamoto H. *Nat Genet* 2001;28:317–325. [PubMed: 11479592]
6. Shah S, Rangarajan S, Friedman SH. *Angew Chem Int Edit* 2005;44:1328–1332.
7. Nguyen QN, Chavli RV, Marques JT, Conrad PG II, Wang D, He W, Belisle BE, Zhang A, Pastor LM, Witney FR, Morris M, Heitz F, Divita G, Williams BRG, McMaster GK. *Biochim Biophys Acta* 2006;1758:394–403. [PubMed: 16497269]
8. Zhang K, Taylor J. *J Am Chem Soc* 1999;121:11579–11580.
9. Ordoukhanian P, Taylor JS. *Bioconjug Chem* 2000;11:94–103. [PubMed: 10639091]
10. Lenox HJ, McCoy CP, Sheppard TL. *Org Lett* 2001;3:2415–2418. [PubMed: 11463330]
11. Tang X, Dmochowski IJ. *Angew Chem Int Ed* 2006;45:3523–3526.
12. Kröck L, Heckel A. *Angew Chem Int Ed* 2005;44:471–473.
13. Mayer G, Krock L, Mikat V, Engeser M, Heckel A. *Chembiochem* 2005;6:1966–1970. [PubMed: 16178038]
14. Tang XJ, Dmochowski IJ. *Org Lett* 2005;7:279–282. [PubMed: 15646977]
15. Höbartner C, Silverman SK. *Angew Chem Int Ed* 2005;44:7305–7309.
16. Ting R, Lerner L, Perrin DM. *J Am Chem Soc* 2004;126:12720–12721. [PubMed: 15469235]
17. Lusic H, Young DD, Lively MO, Deiters A. *Org Lett* 2007;9:1903–1906. [PubMed: 17447773]
18. Lusic H, Lively MO, Deiters A. *Mol Biosyst* 2008;4:508–511. [PubMed: 18493645]
19. Denk W, Strickler JH, Webb WW. *Science* 1990;248:73–76. [PubMed: 2321027]
20. Piston DW. *Trends Cell Biol* 1999;9:66–69. [PubMed: 10087621]
21. Fisher WG, Partridge WP, Dees C, Wachter EA. *Photochem Photobiol* 1997;66:141–155. [PubMed: 9277135]
22. Kollias N, Zonios G, Stamatas GN. *Vib Spectrosc* 2002;28:17–23.
23. Detty MR, Gibson SL, Wagner SJ. *J Med Chem* 2004;47:3897–3915. [PubMed: 15267226]
24. Zhu Y, Pavlos CM, Toscano JP, Dore TM. *J Am Chem Soc* 2006;128:4267–4276. [PubMed: 16569001]
25. Furuta T, Wang SS, Dantzker JL, Dore TM, Bybee WJ, Callaway EM, Denk W, Tsien RY. *Proc Natl Acad Sci USA* 1999;96:1193–1200. [PubMed: 9990000]
26. Furuta T, Noguchi K. *Trac-Trends Anal Chem* 2004;23:511–519.
27. Furuta T, Takeuchi H, Isozaki M, Takahashi Y, Kanehara M, Sugimoto M, Watanabe T, Noguchi K, Dore TM, Kurahashi T, Iwamura M, Tsien RY. *Chembiochem* 2004;5:1119–1128. [PubMed: 15300837]
28. Fedoryak OD, Dore TM. *Org Lett* 2002;4:3419–3422. [PubMed: 12323033]
29. Lu M, Fedoryak OD, Moister BR, Dore TM. *Org Lett* 2003;5:2119–2122. [PubMed: 12790543]
30. Suzuki AZ, Watanabe T, Kawamoto M, Nishiyama K, Yamashita H, Ishii M, Iwamura M, Furuta T. *Org Lett* 2003;5:4867–4870. [PubMed: 14653694]
31. Furuta T, Watanabe T, Tanabe S, Sakyo J, Matsuba C. *Org Lett* 2007;9:4717–4720. [PubMed: 17929824]
32. Schmidt R, Geissler D, Hagen V, Bendig J. *J Phys Chem A* 2007;111:5768–5774. [PubMed: 17564421]
33. Momotake A, Lindegger N, Niggli E, Barsotti RJ, Ellis-Davies GCR. *Nat Methods* 2006;3:35–40. [PubMed: 16369551]
34. Lusic H, Deiters A. *Synthesis* 2006:2147–2150.
35. Young DD, Deiters A. *Bioorg Med Chem Lett* 2006;16:2658–2661. [PubMed: 16513347]
36. Ellis-Davies, GCR.; Momotake, A. US Patent Application. 20080188645. 2008.

37. Lan T, McLaughlin LW. J Am Chem Soc 2000;122:6512–6513.



1: $\text{R}^1 = \text{OH}$, $\text{R}^2 = \text{CH}_3$

2: $\text{R}^1 = \text{Br}$, $\text{R}^2 = \text{CH}_3$

3: $\text{R}^1 = \text{Br}$, $\text{R}^2 = \text{H}$

4: $\text{R}^1 = \text{OCH}_2\text{Cl}$, $\text{R}^2 = \text{CH}_3$

Figure 1.
The NDBF caging group derivatives **1–4**.






Figure 2.
Decaging timecourse of NBDF-thymidine.



Scheme 1.
Synthesis of NDBF based caging groups **1**, **2**, and **4**.



Scheme 2.
Synthesis of the NDBF-caged thymidine phosphoramidite **11**.